Boccon-Gibod L - Search Results

1

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.

Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Isbarn H, et al. Eur Urol. 2009 Jan;55(1):62-75. doi: 10.1016/j.eururo.2008.10.008. Epub 2008 Oct 14. Eur Urol. 2009. PMID: 18945543 Free PMC article. Review.

2

Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.

Abrahamsson PA, Anderson J, Boccon-Gibod L, Schulman C, Studer UE, Wirth M. Abrahamsson PA, et al. Eur Urol. 2005 Dec;48(6):900-5. doi: 10.1016/j.eururo.2005.09.005. Epub 2005 Oct 11. Eur Urol. 2005. PMID: 16257109 Review.

3

Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.

Boccon-Gibod L, Albers P, Morote J, van Poppel H, de la Rosette J, Villers A, Malmberg A, Neijber A, Montorsi F. Boccon-Gibod L, et al. Eur Urol. 2014 Oct;66(4):655-63. doi: 10.1016/j.eururo.2014.05.037. Epub 2014 Jun 18. Eur Urol. 2014. PMID: 24954791 Clinical Trial.

4

Is seminal vesicle ablation mandatory for all patients undergoing radical prostatectomy? A multivariate analysis on 1283 patients.

Zlotta AR, Roumeguère T, Ravery V, Hoffmann P, Montorsi F, Türkeri L, Dobrovrits M, Scattoni V, Ekane S, Bollens R, Vanden Bossche M, Djavan B, Boccon-Gibod L, Schulman CC; European Society for Urological Oncology. Zlotta AR, et al. Eur Urol. 2004 Jul;46(1):42-9. doi: 10.1016/j.eururo.2004.03.021. Eur Urol. 2004. PMID: 15183546

5

Chemotherapeutic prevention studies of prostate cancer.

Djavan B, Zlotta A, Schulman C, Teillac P, Iversen P, Boccon Gibod L, Bartsch G, Marberger M. Djavan B, et al. J Urol. 2004 Feb;171(2 Pt 2):S10-3; discussion S13-4. doi: 10.1097/01.ju.0000108221.63466.7d. J Urol. 2004. PMID: 14713746 Review.

6

Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?

Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M. Djavan B, et al. J Urol. 2001 Nov;166(5):1679-83. J Urol. 2001. PMID: 11586201

7

Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.

Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V, Pagano F, Bassi P, Boccon-Gibod L, Ravery V, Treiber U, Ishak L. Leyh H, et al. Eur Urol. 1999 Jan;35(1):52-6. doi: 10.1159/000019819. Eur Urol. 1999. PMID: 9933795 Clinical Trial.

8

Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.

Abrahamsson PA, Boccon-Gibod L, Morote J, de Jong IJ, Malmberg A, Neijber A, Albers P. Abrahamsson PA, et al. Among authors: boccon gibod l. Eur Urol Focus. 2017 Oct;3(4-5):470-479. doi: 10.1016/j.euf.2015.12.008. Epub 2016 Jan 22. Eur Urol Focus. 2017. PMID: 28753747 Clinical Trial.

9

Maximum androgen blockade in 1996.

Boccon-Gibod L. Boccon-Gibod L. Eur Urol. 1996;30 Suppl 1:15-8; discussion 19-21. doi: 10.1159/000474239. Eur Urol. 1996. PMID: 8977985 Review.

10

Nonsteroidal antiandrogen monotherapy of metastatic cancer of the prostate.

Boccon-Gibod L. Boccon-Gibod L. Eur Urol. 1993;24 Suppl 2:77-80. doi: 10.1159/000474396. Eur Urol. 1993. PMID: 8262131

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

530 results

Search Page

Filters